ARTHARAL TABLETS

Indications

• Treatment of mania
• Treatment of bipolar disorder
• Prophylaxis of recurrent depression
• Prophylaxis of aggressive or self-harming behavior

Dosage

Children: Dose adjusted according to serum-lithium concentration; doses are initially divided throughout the day, but once daily administration is preferred when serum-lithium concentration is stabilized.

Adults: Initially 450–675 mg twice daily, adjusted according to serum-lithium concentration; doses are initially divided throughout the day, but once daily administration is preferred when serum-lithium concentration is stabilized.

Mechanism of action

Lithium exerts its therapeutic effects primarily through the inhibition of inositol monophosphatase and the modulation of glutamate levels in the brain. It influences intracellular signaling pathways, particularly those involving phosphoinositide metabolism, which plays a crucial role in synaptic transmission and neuroprotection. Additionally, lithium affects the serotoninergic and dopaminergic systems, contributing to mood stabilization.

Pharmacodynamics

Lithium's pharmacodynamic profile includes mood stabilization, reduction in the frequency and severity of manic episodes, and prevention of recurrent depressive episodes. Its effects are attributed to alterations in neurotransmitter levels and synaptic function, particularly through increased serotonin receptor sensitivity and decreased norepinephrine release.

Pharmacokinetics

Lithium is absorbed quickly from the gastrointestinal tract, with peak plasma concentrations occurring within 1-3 hours post-administration. It has a volume of distribution of about 0.7 L/kg and is primarily excreted unchanged by the kidneys. The half-life of lithium varies but is approximately 24 hours in patients with normal renal function. Serum lithium levels must be monitored to avoid toxicity, with therapeutic ranges typically between 0.6 and 1.2 mmol/L.

Adverse effects

• Nausea
• Vomiting
• Diarrhea
• Dizziness
• Tremors
• Weight gain
• Thyroid dysfunction
• Nephrotoxicity
• Cardiac arrhythmias
• Cognitive impairment

Interactions

• Diuretics may increase the risk of lithium toxicity
• Non-steroidal anti-inflammatory drugs (NSAIDs) may increase lithium levels
• Antidepressants may interact with lithium, especially SSRIs
• Antiepileptic drugs may alter lithium levels

Precautions

• Monitor renal function regularly
• Assess thyroid function periodically
• Use caution in patients with cardiovascular disease
• Monitor sodium intake as it affects lithium levels
• Adjust dosage in elderly patients due to decreased renal function

Pregnancy

Lithium should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Risks include teratogenic effects, particularly during the first trimester.

Breast-feeding

Lithium is excreted in human milk. Caution is advised when administering to nursing mothers, and monitoring of the infant for signs of lithium toxicity is recommended.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

• Lithium citrate 250 mg tablets
• Lithium citrate liquid formulation

Dosage

Children: Specific dosing information is not available for carbonicum. Its levels in the body are generally maintained through normal physiological processes.

Adults: Specific dosing information is not available for carbonicum. Its levels in the body are generally maintained through normal physiological processes.

Mechanism of action

Carbon dioxide acts as a signaling molecule in various physiological pathways. It is involved in the regulation of blood pH, respiratory drive, and vasodilation. Elevated levels of carbon dioxide in the blood lead to respiratory acidosis, stimulating the respiratory center in the brain to increase ventilation and expel excess CO2, thus regulating acid-base balance.

Pharmacodynamics

Carbon dioxide is a naturally occurring compound that influences various systems in the body. It helps in the transport of oxygen from the lungs to the tissues and assists in the regulation of blood pH. The presence of CO2 in the blood affects the affinity of hemoglobin for oxygen, a phenomenon known as the Bohr effect, which enhances oxygen delivery to tissues during states of increased metabolism.

Pharmacokinetics

Carbon dioxide is produced endogenously during cellular respiration and is eliminated primarily via the lungs. It diffuses readily across biological membranes due to its gaseous state. The body maintains homeostasis of carbon dioxide levels tightly through respiratory and metabolic mechanisms. The half-life of carbon dioxide in the blood is very short, as it is continuously being produced and exhaled.

Pregnancy

Safety during pregnancy has not been established. Consult a healthcare provider before use.

Breast-feeding

It is unknown whether carbonicum is excreted in human milk. Caution is advised when administering to breastfeeding women.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Iron deficiency anemia
• Prevention of iron deficiency in high-risk populations
• Adjuvant therapy in chronic blood loss conditions

Dosage

Children: Paediatric dosing should be determined based on age, weight, and severity of deficiency. It is essential to refer to the BNF for Children for appropriate dosing information.

Adults: Adult dosing typically depends on the severity of iron deficiency and the specific formulation of iron used. It is advisable to refer to established guidelines or the BNF for specific dosing recommendations.

Mechanism of action

Ferrium works by replenishing iron stores in the body, enhancing the synthesis of hemoglobin and promoting normal erythropoiesis (the production of red blood cells). Iron is absorbed mainly in the duodenum and proximal jejunum, where it enters the bloodstream and is transported to various tissues, including the bone marrow, for incorporation into hemoglobin.

Pharmacodynamics

The pharmacodynamic effects of ferrium include increased hemoglobin levels, improved oxygen transport capacity, and alleviation of symptoms associated with anemia such as fatigue and weakness. It is important to monitor hemoglobin levels and iron stores to assess the effectiveness of therapy and avoid iron overload.

Pharmacokinetics

Ferrium is generally absorbed in the gastrointestinal tract, with absorption rates varying based on the form of iron and the presence of food. The bioavailability of iron can be enhanced by consuming it on an empty stomach. Once absorbed, iron is transported bound to transferrin in the plasma, and it is stored in the liver and spleen as ferritin. The body regulates iron homeostasis tightly, with no active excretion mechanisms, which can lead to potential toxicity if excessive amounts are administered.

Contra-indications

• Hypersensitivity to ferric compounds
• Hemochromatosis
• Hemosiderosis
• Active liver disease
• Severe renal impairment

Adverse effects

• Gastrointestinal disturbances
• Nausea
• Constipation
• Diarrhea
• Staining of teeth
• Anaphylactic reactions
• Iron overload

Interactions

• Antacids may reduce the absorption of iron
• Tetracycline antibiotics may form insoluble complexes with iron
• Chloramphenicol may interfere with iron absorption
• Vitamin C may enhance iron absorption

Precautions

• Use with caution in patients with liver disease
• Monitor iron levels in patients receiving long-term therapy
• Assess for signs of iron overload
• Consider dietary sources of iron

Pregnancy

Iron is essential during pregnancy for fetal development, but supplementation should be based on individual needs and monitored by a healthcare provider.

Breast-feeding

Iron is excreted in breast milk; supplementation may be necessary to maintain maternal iron stores, but should be done under guidance.

Storage

Store in a cool, dry place, away from direct sunlight. Keep out of reach of children to prevent accidental overdose.

Formulations

• Oral tablets
• Liquid formulations
• Injectable solutions

Indications

• Bipolar disorder
• Acute mania
• Adjunctive treatment for depression

Dosage

Children: Refer to the BNF for Children for specific dosing information for paediatric patients, as it varies based on age and weight.

Adults: The usual starting dose for the treatment of acute mania is 900 to 1200 mg per day, divided into two or three doses. Maintenance doses usually range from 600 to 900 mg per day, adjusted based on serum lithium levels.

Mechanism of action

The exact mechanism of action of lithium is not fully understood. However, it is believed to influence neurotransmitter release and receptor sensitivity, particularly in relation to serotonin and norepinephrine. Lithium also affects second messenger systems, particularly inositol monophosphate and cyclic AMP, which play critical roles in neuronal signaling and mood regulation.

Pharmacodynamics

Lithium exhibits mood-stabilizing effects, decreasing the severity and frequency of mood swings in individuals with bipolar disorder. It has anti-manic effects that can lead to a reduction in symptoms such as euphoria, irritability, and hyperactivity. Lithium also has neuroprotective properties and may enhance neuronal survival and function.

Pharmacokinetics

Lithium is absorbed from the gastrointestinal tract and achieves peak plasma concentrations within 1 to 3 hours after oral administration. It has a volume of distribution of approximately 0.7 L/kg and is primarily excreted unchanged by the kidneys. The half-life of lithium can vary from 18 to 36 hours, and it requires careful monitoring to maintain therapeutic levels, as the therapeutic range is narrow.

Contra-indications

• Severe renal impairment
• Cardiovascular disease
• Dehydration
• Hypersensitivity to lithium

Adverse effects

• Nausea
• Diarrhea
• Tremors
• Weight gain
• Polyuria
• Thyroid dysfunction
• Cognitive impairment
• Kidney damage

Interactions

• mexiletine: Severe (affects exposure)
• ace inhibitors: Moderate (increases concentration)
• metronidazole: Moderate (increases concentration)
• tetracyclines: Moderate (increases risk of lithium toxicity)
• theophylline: Moderate (decreases concentration)
• acetazolamide: Unknown (affects concentration)
• aminophylline: Unknown (decreases concentration)
• sodium bicarbonate: Unknown (decreases concentration)
• zuclopenthixol: Unknown (increases risk of neurotoxicity)
• eplerenone: Unknown (increases concentration)

Precautions

• Monitor renal function regularly
• Assess thyroid function prior to treatment
• Careful use in patients with cardiovascular conditions
• Ensure adequate hydration
• Monitor for signs of lithium toxicity

Pregnancy

Use with caution, potential risk of teratogenic effects. Monitor closely if used during pregnancy.

Breast-feeding

Lithium is excreted in breast milk. Caution is advised; monitor infant for signs of toxicity.

Storage

Store at room temperature, away from light and moisture. Keep out of reach of children.

Formulations

• Oral tablets
• Oral solution

Indications

• Hyponatremia
• Dehydration
• Maintenance of electrolyte balance
• Fluid replacement therapy

Dosage

Children: Dosage is highly variable and must be determined by a healthcare professional based on the child's clinical condition and needs.

Adults: Dosage is highly variable and depends on the clinical condition being treated. Clinical guidelines should be consulted for specific dosing regimens.

Mechanism of action

Sodium primarily acts by influencing the movement of water across cell membranes and is crucial for the generation and transmission of action potentials in excitable tissues. It is involved in the sodium-potassium pump (Na+/K+ ATPase), which maintains the electrochemical gradient across cell membranes, essential for cellular functions.

Pharmacodynamics

Sodium has a key role in maintaining fluid balance and blood pressure. It modulates the osmotic pressure of body fluids and is essential for the regulation of blood volume. Changes in sodium levels can lead to various clinical conditions, including hypernatremia or hyponatremia, which can significantly impact cardiovascular, renal, and neurological functions.

Pharmacokinetics

Sodium is absorbed primarily in the gastrointestinal tract, with renal excretion being the main route of elimination. Its plasma half-life is not well-defined, as it is continuously regulated by homeostatic mechanisms involving the kidneys and hormonal systems, particularly aldosterone. Sodium levels in the body are tightly controlled, and dietary intake can vary widely without significant fluctuations in serum sodium concentration.

Contra-indications

• Hypernatremia
• Severe renal impairment
• Heart failure

Adverse effects

• Hypertension
• Fluid retention
• Edema
• Tachycardia
• Nausea
• Vomiting
• Headache

Interactions

• Diuretics (especially thiazide and loop diuretics)
• ACE inhibitors
• Angiotensin receptor blockers (ARBs)
• Non-steroidal anti-inflammatory drugs (NSAIDs)

Precautions

• Monitor electrolyte levels
• Use cautiously in patients with cardiovascular disease
• Consider renal function before use

Pregnancy

Use only if clearly needed and the benefits outweigh the risks; monitor closely.

Breast-feeding

Generally considered safe when used appropriately; monitor for any adverse effects in the infant.

Storage

Store at room temperature, away from moisture and heat. Keep out of reach of children.

Formulations

• Oral tablets
• Oral solution
• Intravenous solution

Indications

• Traditional medicine for various ailments
• Potential use in managing cardiovascular conditions (with caution)
• Herbal remedies for symptomatic relief of certain conditions

Dosage

Children: Dosage information for pediatric use is not available. Consultation with a healthcare professional is advised.

Adults: Dosage information is not standardized due to the lack of clinical studies and potential toxicity. Consultation with a healthcare professional is advised.

Mechanism of action

The pharmacological effects of rhododendron are primarily attributed to the presence of grayanotoxins, which act on sodium channels in the nervous system. These compounds can lead to prolonged depolarization of nerve membranes, resulting in altered neurotransmission. This mechanism may contribute to both the therapeutic effects and toxicity observed with rhododendron ingestion.

Pharmacodynamics

Grayanotoxins exhibit a unique pharmacodynamic profile by binding to sodium channels, causing them to remain in an open state. This action can lead to an increase in intracellular sodium levels, resulting in prolonged action potentials. The effect on the cardiovascular system can include bradycardia and hypotension, while effects on the central nervous system may include dizziness and confusion.

Pharmacokinetics

The pharmacokinetics of rhododendron compounds, particularly grayanotoxins, are not well characterized in humans. After ingestion, these compounds may be rapidly absorbed in the gastrointestinal tract, leading to systemic effects. The metabolism and excretion pathways have not been extensively studied, but toxicity can arise quickly, necessitating prompt medical attention in cases of overdose.

Adverse effects

• Allergic reactions
• Gastrointestinal disturbances
• Headaches
• Dizziness
• Skin rashes

Precautions

• Use with caution in individuals with known allergies to plants in the Ericaceae family
• Monitor for potential gastrointestinal side effects

Pregnancy

Limited data available; consult healthcare provider before use.

Breast-feeding

Limited data available; consult healthcare provider before use.

Storage

Store in a cool, dry place, away from direct sunlight.

Formulations

• Dried leaves
• Extracts
• Capsules
• Teas

Indications

• Contact dermatitis
• Allergic reactions to urushiol
• Inflammatory skin conditions

Dosage

Children: Specific pediatric dosing for Rhus is not established. Consult relevant guidelines for management of allergic reactions in children.

Adults: Dosage for Rhus is not typically established in conventional medicine due to its nature as a plant extract. For management of allergic reactions, supportive care and antihistamines are recommended.

Mechanism of action

The primary active component, urushiol, binds to skin proteins, modifying them and creating a hapten-protein complex. This complex elicits an immune response, leading to delayed-type hypersensitivity reactions, characterized by inflammation, redness, and itching. The immune response is mediated by T-lymphocytes, which recognize the modified proteins as foreign.

Pharmacodynamics

Rhus exhibits anti-inflammatory effects, primarily through the modulation of cytokine release and immune cell activity. However, in sensitive individuals, it can provoke severe inflammatory responses, resulting in contact dermatitis. The severity of the reaction depends on individual sensitivity and the amount of urushiol exposure.

Pharmacokinetics

The absorption of urushiol occurs primarily through the skin upon contact. Once absorbed, it induces a localized immune response. The systemic absorption is minimal, but in cases of extensive exposure, it may enter the bloodstream, potentially leading to widespread allergic reactions. The elimination of urushiol is not well characterized, but it is believed to be metabolized in the liver and excreted via urine, with a half-life that is variable based on the extent of exposure and individual factors.

Pregnancy

Rhus species, particularly those containing toxic components, should be used with caution during pregnancy due to the potential for adverse effects on fetal development. It is best to avoid use unless specifically prescribed by a healthcare professional.

Breast-feeding

Caution is advised when using Rhus products while breastfeeding, as there is limited information on the safety and effects of these substances in nursing infants.

Storage

Store in a cool, dry place away from direct sunlight. Ensure that products are kept out of reach of children.

Dosage

Children: There are no pediatric dosages established for sulphuricum as it is not a therapeutic agent. Refer to safety guidelines for exposure management.

Adults: Sulphuricum is not used therapeutically in adults. Refer to established protocols for handling and exposure management.

Mechanism of action

The mechanism of action of sulphuricum is primarily based on its strong acidic properties. It acts as a dehydrating agent, promoting oxidative reactions that can lead to the formation of reactive oxygen species (ROS). This can result in cellular damage and inflammation, although these effects are generally not desirable in a therapeutic context. In biological systems, sulphur can also play a role in various biochemical pathways, including the synthesis of amino acids and the metabolism of certain drugs.

Pharmacodynamics

Pharmacodynamically, sulphuricum exhibits strong acidic effects, which can lead to significant alterations in cellular environments. It can influence metabolic pathways by affecting enzyme activity and cellular signaling processes, particularly those related to oxidative stress. The compound's capacity to generate reactive oxygen species can contribute to inflammation and cellular damage, which may have implications in various diseases, although these properties are not typically harnessed for therapeutic benefit.

Pharmacokinetics

Sulphuricum is not absorbed or metabolized in the traditional sense as a pharmaceutical compound. Its effects are largely local, and exposure is typically via inhalation, ingestion, or dermal contact, leading to corrosive damage rather than systemic pharmacokinetics. Due to its strong acidic nature, it can cause immediate tissue damage upon contact. Safety measures are critical when handling sulphuricum to prevent harmful exposure.

Adverse effects

• Skin irritation
• Burning sensation
• Dryness
• Erythema

Precautions

• Use with caution in patients with sensitive skin
• Perform a patch test before extensive use
• Avoid contact with eyes

Pregnancy

Use during pregnancy only if clearly needed and prescribed by a healthcare provider.

Breast-feeding

Consult a healthcare provider before use while breastfeeding.

Storage

Store in a cool, dry place away from direct sunlight.

Formulations

• Topical ointment
• Cream
• Lotion

Indications

• Contact dermatitis due to exposure to poison ivy, poison oak, or poison sumac
• Management of allergic skin reactions

Dosage

Children: For children, treatment approaches are similar to adults, but dosing for medications should be based on age and weight. Refer to pediatric dosing guidelines or consult a healthcare provider.

Adults: Treatment typically involves topical corticosteroids, oral antihistamines, and soothing lotions. Dosage should be guided by clinical judgment and specific product instructions.

Mechanism of action

Urushiol, the active compound in Toxicodendron, binds to skin proteins, modifying them and triggering an immune response. This results in the activation of T cells, which leads to an inflammatory response in sensitized individuals. The immune response is characterized by the activation of CD4+ T-helper cells and the recruitment of additional inflammatory cells to the site of exposure.

Pharmacodynamics

The allergic reaction induced by urushiol typically manifests within 12 to 48 hours after exposure, peaking at about 24 to 72 hours. Symptoms include erythema, edema, and vesicle formation. The severity of the reaction can be influenced by factors such as previous sensitization, dose of urushiol, and individual immune response.

Pharmacokinetics

Urushiol is not systemically absorbed through intact skin; however, when applied to damaged skin or through mucous membranes, it can enter the bloodstream. The half-life of urushiol in the body is not well characterized, as it primarily exerts its effects locally on the skin. The compound is metabolized by the liver and is excreted through bile and urine.

Adverse effects

• Skin irritation
• Allergic contact dermatitis
• Rash
• Itching
• Erythema

Precautions

• Avoid contact with skin and mucous membranes
• Wash hands thoroughly after handling
• Use protective clothing when handling

Pregnancy

Safety during pregnancy has not been established. Use with caution.

Breast-feeding

Safety during breastfeeding has not been established. Use with caution.

Storage

Store in a cool, dry place away from direct sunlight.

Formulations

• Topical preparations
• Ointments
• Creams

Indications

• Stimulation of appetite
• Enhancement of vitality
• Potential use in specific cases of muscle weakness (historically)

Dosage

Children: For pediatric dosing, consult the BNF for Children, as appropriate dosing must be determined based on age and weight.

Adults: For specific dosing, refer to professional resources or clinical guidelines, as doses can vary based on the indication and formulation.

Mechanism of action

The primary active component, strychnine, acts as a competitive antagonist at glycine receptors in the spinal cord and brainstem. By inhibiting inhibitory neurotransmission (glycinergic signaling), strychnine leads to increased neuronal excitability and can cause hyperreflexia and convulsions. The mechanism results in heightened motor activity and can be life-threatening due to the potential for respiratory failure.

Pharmacodynamics

Strychnine exhibits a narrow therapeutic index, meaning that small increases in dose can lead to significant toxicity. Its effects can manifest as increased muscle tone, spasms, and hyperactivity. In toxic doses, it can cause generalized muscle contractions and can affect autonomic functions, leading to complications such as respiratory distress and cardiovascular instability.

Pharmacokinetics

Strychnine is rapidly absorbed from the gastrointestinal tract and has a volume of distribution that indicates extensive tissue binding. It undergoes hepatic metabolism and is primarily excreted in the urine. The half-life of strychnine ranges from 9 to 12 hours, but this can vary significantly based on individual metabolic factors. The onset of action occurs within 15 to 30 minutes after ingestion, with peak effects observed within a few hours.

Pregnancy

Vomica is not recommended during pregnancy due to potential risks and lack of safety data.

Breast-feeding

It is advised to avoid using vomica while breastfeeding due to insufficient safety information.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.